Study S002473

Improving Screening and Therapy Provision Among Hispanics/Latinx at Risk for Chronic Kidney Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT05734989
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 248
Start: 2023-05-18
Primary completion: 2025-04-04
Lead sponsor: Duke University
Conditions: Type 2 Diabetes; Chronic Kidney Diseases
Interventions: DIAGNOSTIC_TEST:BP; DIAGNOSTIC_TEST:HbA1c; BEHAVIORAL:PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Number of Participants Who Attended or Scheduled a Primary Care Physician (PCP) Visit [up to 3 months after screening]
Number of Participants Who Received Urine Albumin-to-Creatinine Ratio (uACR) Screening [Within three months of T0 (primary care appointment)]
Number of Participants Who Were Prescribed an SGLT2 Inhibitor (SGLT2i) and/or a GLP-1 Receptor Agonist (GLP-1 RA) [Within three months of T0 (primary care appointment)]
Number of Participants Who Were Prescribed a Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) [Within three months of T0 (primary care appointment)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.